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ABSTRACT
Breast cancer is the most frequently occurring cancer in women and is the second
leading cause of death. About 40% of breast cancers are hormone-dependent and require
estrogen for their growth. The steroid sulfatase pathway is an important means of
converting local inactive estrogens to their active forms, thus supporting tumor growth. A
substantial amount of research has been performed in the design of steroid sulfatase
inhibitors, but the regulation of steroid sulfatase has been largely overlooked. My goal
was to study the regulation of steroid sulfatase by different steroid hormones, using two
human breast cancer cell lines the hormone-dependent MCF-7, and the hormone-
independent MDA-MB-231. I also studied the effect of various growth factors (oxytocin,
prolactin, IGF-1 and EGF) on steroid sulfatase activity of MDA-MB-231 cells. MDA-
MB-231 cells treated in whole growth medium showed a decrease in steroid sulfatase
activity, whereas, those treated with cortisol had an decrease in steroid sulfatase activity.
Estradiol and estrone sulfate had no effect on steroid sulfatase activity in MDA-MB-231
cells. No differences in steroid sulfatase activity were found for any treatments in
hormone-dependent MCF-7 cells. Growth factors also did not have any effect on the
steroid sulfatase activity in MDA-MB-231 cells. Recent evidence shows that steroid
sulfatase immunoreactivity is associated with breast cancer relapse. Hence, steroid
sulfatase could be an independent predictive marker for breast cancer. My other aim was
to evaluate different human tissues for steroid sulfatase status by immunohistochemistry.
The results showed that placenta, liver, normal breast, breast carcinoma (ER+/ PR+) and
skeletal muscle had high immunoreactivity for steroid sulfatase. Skin, lung, brain and
vuterine carcinoma showed moderate steroid sulfatase activity, whereas, adrenal gland,
breast carcinoma (ER-/ PR-), ovarian carcinoma and prostate had very low steroid
sulfatase activity. The study of regulation and inhibition of steroid sulfatase may be
important in treatment, prognosis and reduction of mortality due to breast cancer.
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1CHAPTER 1
Background
Breast cancer
Breast cancer is the most commonly occurring cancer among women and it is the
second leading cause of death due to cancers in women. During 2002, about 203,500 new
cases of invasive breast cancer are expected to occur among women in United States and
about 40,000 persons are expected to die of breast cancer this year (American Cancer
Society, 2002). Although men can have breast cancer, it is much less common than in
women.
Breast cancer can be categorized as either hormone-dependent or hormone-
independent. About 40% of breast cancers are hormone-dependent, meaning that growth
of these cells require hormones. The most important hormones in this respect are
estradiol and androstenediol (Ahmed et al., 2002). Hormone-dependent tumor cells
express estrogen receptor (ER). In contrast, hormone-independent breast cancer cells do
not express ER and steroid hormone is not required for tumor growth. Before selecting
treatment, it becomes important to determine if a breast tumor is hormone-dependent or
hormone-independent, because treatment methods are different.
Effective ways of treating hormone-dependent cancers can be to block the
hormone-receptor or to inhibit hormone synthesis. Several clinical treatments use one of
these strategies.   For example, tamoxifen is an anti-estrogen used as an endocrine
treatment for breast cancer. Tamoxifen blocks the binding of estrogens to estrogen
receptor of human breast cancer cells (Jordan, 1997). In an alternative strategy,
2formestane, exemestane and anastrozole (Brodie, 2002) are inhibitors of aromatase,
which is important in estrogen synthesis.
Steroid sulfatase is an enzyme in another synthetic pathway for estrogens with
potential for use in clinical treatment of hormone-dependent cancers. Steroid sulfatase
converts various inactive hormones into their active forms by cleaving their sulfate
group. This enzyme is implicated in support of  hormone-dependent cancers by providing
the estrogen locally for the growth of hormone-dependent breast cancer tissue (Santner et
al., 1986; Reed and Purohit, 1997).
Aromatase is the enzyme that forms estrogens from androgens, but it appears that
steroid sulfatase may play a more important role in formation of estrogens within
cancerous tissue. Steroid sulfatase is found in a greater percentage of breast cancers than
aromatase and its activity is about 10-times greater than aromatase activity (Santner et al.,
1984). Also, steroid sulfatase mRNA levels are markedly increased in breast cancer
tissues (Utsumi et al., 2000). Thus, the steroid sulfatase pathway appears to be
quantitatively more important than the aromatase pathway in local production of
estrogens in cancer cells (Pasqualini et al., 1996).
Not only do estrogens themselves, but also estrogenic androgens, play a crucial
role in supporting hormone-dependent tumors. Dehydroepiandrosterone sulfate (DHEAS)
is acted upon by steroid sulfatase to form dehydroepiandrosterone (DHEA). Thereafter,
DHEA is converted to androstenediol (ADIOL) by 17-ketoreductase. ADIOL is an
androgen that mimics estradiol by binding to estrogen receptor, causing estrogenic
effects, such as increasing the synthesis of estrogen and progesterone receptors (Adams,
1998). These effects are not caused by conversion of ADIOL to estradiol (van Doorn et
3al., 1981). At concentrations present in normal women, ADIOL can act as estrogen in
MCF-7 cells (Adams et al., 1981). ADIOL stimulates proliferation of human breast
cancer tissue at concentrations normally present in women (Poulin and Labrie, 1986).
Another important aspect of steroid sulfatase is its relationship compared to
prognosis of cancer. Steroid sulfatase activity is about three times higher in human breast
cancer than in nonmalignant breast tissue (Utsumi et al., 2000). Also, high levels of
steroid sulfatase activity are associated with decrease in relapse-free interval. In other
words, increase in steroid sulfatase level is associated with relapse (Utsumi et al., 1999).
These data suggest that steroid sulfatase could be an independent indicator of prognosis
of breast cancer. At present, various prognostic factors are used clinically to help in
treatments, such as tumor size, lymph node involvement, distant metastasis and presence
of estrogen and progesterone receptor. Use of additional indicators, such as steroid
sulfatase status, may further help in assessment and treatment. Recent studies show that
steroid sulfatase mRNA levels are elevated in ER-positive breast cancer but not in ER-
negative breast cancers (Miyoshi et al., 2003). Another group (Suzuki et al., 2003)
studied the steroid sulfatase immunoreactivity in human breast cancer and found that
steroid sulfatase expression was present only in carcinoma cells and was associated with
increased recurrence and poor prognosis. Hence, it would be worthwhile to test breast
cancers for steroid sulfatase status and to assess them as a marker for diagnosis and
relapse.
To perform such a study requires a steroid sulfatase antibody, such as the one that
has been prepared in Dr. Selcers’ laboratory (Selcer et al., 2001). Earlier, a few
researchers had used steroid sulfatase antibody but those were prepared by purifying the
4steroid sulfatase to some extent from placenta and then injecting it into a rabbit or mouse
so as to get the antiserum. Dr. Selcer’s laboratory used a different approach. Here, the
cDNA sequences of human, rat and mouse steroid sulfatases were aligned, and a
conserved region was selected, taking into consideration the following factors –
homology among the species, lack of homology to other proteins, high antigenicity,
location away from steroid sulfatase active site, and the membrane spanning region. A
peptide was synthesized using the sequence selected, coupled with keyhole limpet
hemocyanin and then injected into rabbits in order to obtain the antisera. Sera obtained
from the rabbits before injecting the antigen are also available to be used as negative
control. The immune antisera have been shown by Western blotting to bind to steroid
sulfatase in various tissues; namely, human placenta, human breast cancer cells (MCF-7
and MDA-MB-231), rat liver, rat granulosa cells, porcine ovaries and monkey ovaries
(Selcer et al., 2001). This antiserum could be used as a tool for carrying out
immunohistochemical studies.
Steroid sulfatase inhibition
Given the potential importance of steroid sulfatase in support of breast cancer,
inhibition of this enzyme may be useful in therapy (Reed and Purohit, 1993). A variety of
inhibitors have been developed. Danazol, a compound used for treating endometriosis,
was one of the first compounds to show inhibition of steroid sulfatase, but it was not very
potent (James et al., 1992). Estrone-3-methylthiophosphonate (E1-3-MTP) mildly
inhibited estrone sulfatase activity in MCF-7 breast cancer cells, human placental and
breast tumor tissues (Duncan et al., 1993). The next compound developed was EMATE,
(estrone-3-O-sulfamate) which is an extremely potent inhibitor of steroid sulfatase
5activity (Reed et al., 1995) and virtually eliminates steroid sulfatase activity in breast
cancer cell lines MDA-MB-231 and MCF-7 (Kolli et al., 1999). The disadvantage of
EMATE is that it is estrogenic (Elger et al., 1995). Hence, new non-estrogenic steroid
sulfatase inhibitors have been designed and synthesized. One of these, COUMATE (4-
methylcoumarin-7-O-sulfamate), is active in vitro (Purohit et al., 1996). Other
compounds synthesized were 3,4-dimethylcoumarin-3-O-sulfamate, 667 COUMATE and
2-methoxyestrone-3-O-sulfamate (2-MeOEMATE) (Woo et al., 1998; Purohit et al.,
2000). 667 COUMATE inhibits DHEAS conversion about 25-times more than EMATE
in a placental microsomal preparation (Woo et al., 2000). Another group of compounds,
the (p-O-sulfamoyl)-N-alkanoyl tyramines, are also potent inhibitors of estrone sulfatase
(Selcer et al., 1997). Additionally, the 17β-(N-alkylcarbamoyl) and 17β-(N-alkanoyl)-
estra-1,3,5,(10)-trien-3-o-sulfamates show anti-steroid sulfatase activity. These
compounds have increased affinity for the steroid sulfatase enzyme and decreased
estrogenic properties (Li et al., 1998). Many of these compounds are under clinical trial
for evaluation as treatments for breast cancer.
Whether a particular inhibitor will be effective in reducing steroid sulfatase
activity depends upon whether the steroid sulfatase enzyme is active at the time when the
inhibitor is being used. Thus, it becomes important to study what factors regulate the
activity of steroid sulfatase, under physiological conditions. At present, not much is
known about the regulation of steroid sulfatase.
Different peptide hormones alter steroid sulfatase activity in the placenta
(Braverman and Gurpide, 1986). Oxytocin is synthesized in the cell bodies of supraoptic
and paraventricular nuclei of the hypothalamus, transported down the axon and released
6from the posterior pituitary. Oxytocin stimulates contraction of myoepithelial cells of
lactating mammary gland and also stimulates contraction of smooth muscles of the uterus
during labor (Robertson, 1995). Prolactin is a hormone that is secreted by the anterior
pituitary. Along with other hormones, prolactin helps in normal breast development and
lactation, by causing synthesis of milk proteins, lipids and carbohydrates (Frohman,
1995). Oxytocin and prolactin stimulate the activity steriod sulfatase in the placenta
before the onset of labor, and inhibit it after labor is initiated (Braverman and Gurpide,
1986).
Various growth factors seem to be involved in regulation of steroid sulfatase.
Insulin-like growth factor 1 (IGF-1) is a mitogen that has anti-apoptotic activity. In a
prospective case-control study, premenopausal women with increased IGF-1 levels (>256
ng/ml) had increased risk of breast cancer (Toniolo et al., 2000). Epidermal growth factor
receptor (EGFR) is expressed by a number of tumors and corresponds to poor prognosis.
EGF, binding to EGFR, leads to activation of a second messenger system that eventually
leads to proliferation and differentiation of the tumor. In breast cancer, a high level of
expression of EGFR is associated with hormone-resistant disease (Morris, 2002).
Antibodies against EGFR, namely anti-HER-2 antibody, are now used in combination
with chemotherapy to modify cellular response and treat breast cancer (Pusztai et al.,
1999). Tumor necrosis factor alpha and interleukin-6 may also increase the activity of
steroid sulfatase in breast cancer by post-translational modification, or by increasing
substrate availability (Newman et al., 2000).
Retinoic acid and carotenoids stimulate the activity of estrone sulfatase in MCF-7
breast cancer cells, but have no effect on its activity in the MDA-MB-231 breast cancer
7cell line (Ng et al., 2000). Synthetic progestins, such as medrogestone, promegestone,
normegestrol acetate and tibolone, inhibit steroid sulfatase in breast cancer cells (Chetrite
et al., 1996; Chetrite et al., 1997; Chetrite et al., 1999). Also, there is evidence that
estradiol-17β inhibits steroid sulfatase activity in estrogen-dependent MCF-7 and T-47D
cells (Pasqualini and Chetrite, 2001). Hence, it seems that steroids may also play an
important role in regulation of steroid sulfatase.
Steroid hormones
Steroid hormones are a class of signaling molecules that have a variety of
functions associated with maintenance of homeostasis. All are derived from cholesterol
and share the same basic ring structure, the cyclopentanoperhydrophenanthrene nucleus.
This consists of 3 six-carbon cyclohexane rings designated as A, B and C rings and a
five-carbon cyclopentane ring denoted as the D ring. On these four rings are attached a
variety of side-groups which confer specificity to the different steroid hormones.
Based on their action, steroid hormones are classified into six groups (Duke et al.,
1995). Glucocorticoids, produced by the adrenal fasciculata and reticularis, play an
important role in carbohydrate metabolism, immunity and stress. Mineralocorticoids,
synthesized in the adrenal glomerulosa, maintain sodium and potassium homeostasis.
Androgens, produced in the adrenal glands and in the testes, are important in male sexual
and reproductive functions. Estrogens, synthesized by the ovarian follicle, are responsible
for a number of female sexual and reproductive functions. Progestins, synthesized by the
ovarian corpus luteum, are responsible for some female sexual and reproductive
functions. Vitamin D, derived from cholecalciferol, has important functions in calcium
metabolism.
8Regardless of the type of steroid hormone, all act through a similar mechanism.
Steroid hormones are present in blood both in free and protein-bound forms. The free
hormone is considered the active form. About 95% of steroid hormones are bound to
plasma transport proteins. These bound hormones are inactive and thus act
as reservoir of steroid.
Steroid hormone receptors
Being hydrophobic, steroids diffuse into the interior of the cell passively. A cell’s
ability to respond to a particular steroid hormone is based on the presence or absence of
specific steroid receptors. Steroids bind to the inactive receptor either in the cytoplasm or
in the nucleus.
The steroid receptors are a family of similar proteins which can be divided into 3
functional domains. Domain I acts to activate gene transcription. Domain II, which
contains a zinc finger motif, is a domain for DNA binding. Domain III is a steroid
binding domain (O'Malley et al., 1991). The steroid receptors are normally associated
with chaperone proteins such as heat shock protein 90. Once the receptor binds with
hormone, it disassociates from the chaperone protein and gains the ability to bind to
DNA. This is known as activation or transformation.
After this, two steroid receptors often dimerize  and bind to DNA sequences in the
nucleus, usually in the proximity of genes regulated by that hormone. There are cis-
elements present at the 5’ upstream region of the gene which control the expression of
steroid-regulated genes. These are promoters, steroid-responsive enhancers, silencers and
hormone-independent enhancers ( O'Malley et al., 1991).
9Promoters include the TATA box and USP ( Upstream promoter) and are
responsible for setting the basal rate of transcription. Enhancers are the DNA-binding
sites for the activated steroid receptor complexes and are called steroid response elements
(SRE). SRE are base pair sequences which are arranged palindromically with respect to
each other with a spacer region in between. The hormone-receptor complex identifies this
specific sequence and binds to each of the two half sites as a dimer. Silencers decrease
the rate of transcription. Hormone-independent enhancers aid the function of SRE. These
interactions affect the transcription of genes in a positive or negative way. Thus, the
steroid hormone receptors can be viewed as ligand-activated transcription factors.
Figure 1 : Synthesis of steroid hormones (adapted from O'Malley et al., 1991)
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Steroid hormone synthesis
Steroid hormones are synthesized from a common precursor, cholesterol (Figure
1). In the first step cholesterol (C27) is converted to pregnenolone (C21) by the enzyme
CYP 450- scc (side chain cleavage) which is present on the inner mitochondrial
membrane (Gill, 1995). This step is the enzymatic rate limiting step in the production of
steroids. In the next step, pregnenolone is converted to progesterone by 3β-
hydroxysteroid dehydrogenase (3β HSD). Further conversions takes place through either
the pregnenolone (∆ 5) or the progesterone (∆ 4) pathways. These lead to formation of
C21 steroids such as cortisol and aldosterone, C19 hormones such as testosterone and
dihydrotestosterone, and C18 steroids such as estrone and estradiol.
The particular steroid hormone that a given tissue produces depends upon the
nature of the tissue and the activity of the enzymes present in that tissue. The adrenal
glands produce significant amount of cortisol and aldosterone, but lesser amounts of
estrogens and testosterone. The testes produce primarily the sex steroid testosterone and
lesser quantities of estrogen. In the ovary, the main pathway is the ∆ 4 pathway, which
forms progesterone, androgens and, more importantly, estrogens from androgens.
Aromatase is a cytochrome P450 (CYP19) present in ovarian granulosa cells, adipose
tissue and placenta (Gill, 1995). It converts androstenedione and testosterone to estrone
(E1) and estradiol (E2), respectively, by aromatization of the A ring.
Steroids produced by one tissue are often modified in other tissues. Steroids can
be conjugated with glucuronic acid by the enzyme glucuronyl transferase. This reaction
takes place in the liver and uridine diphosphoglucuronic acid is the glucuronide donor.
Glucuronidation makes the steroid more water-soluble and is a process of
11
inactivation for excretion of steroids (O'Malley et al., 1991). Another peripheral
conversion is testosterone to dihydrotestosterone, which is a more potent form of
testosterone, by the enzyme 5α reductase.
Steroid sulfatase (EC 3.1.6.2) is an enzyme that removes the sulfate group from 3-
hydroxysteroid sulfates, such as cholesterol-3-sulfate, dehydroepiandrosterone-3-sulfate
and estrone-3-sulfate. It converts dehydroepiandrosterone sulfate (DHEAS) to
dehydroepiandrosterone and estrone sulfate to estrone (Purohit et al., 1994). It is
primarily localized to the endoplasmic reticulum (Chang et al., 1986). Liver and placenta
express steroid sulfatase (Shankaran et al., 1991). Munroe and Chang (1987), showed
expression of steroid sulfatase in adrenal gland, muscle, spleen, thyroid gland, heart,
lung, intestine and ovary. The steroid sulfatase gene Sts is present on the distal portion of
the short arm of the X-chromosome and is non-functional on the Y-chromosome (Yen et
al., 1987).
12
Specific Aims
1) (a) To determine the effect of steroid hormones (cortisol, estradiol,
estrone sulfate, EMATE and those in whole growth media) on steroid sulfatase activity in
human breast cancer cell lines (MDA-MB-231 and MCF-7).
    (b) To determine the effect of various growth factors (prolactin, oxytocin
IGF-1 and EGF) on steroid sulfatase activity in the hormone-independent breast cancer
cell line MDA-MB-231.
2) To screen various human tissues for steroid sulfatase status using
immunohistochemistry.
13
CHAPTER 2
Experimental Design
Specific aim 1) (a) To determine the effect of steroid hormones (cortisol, estradiol,
estrone sulfate, EMATE and those in whole growth media) on steroid sulfatase activity in
human breast cancer cell lines (MDA-MB-231 and MCF-7).
Model systems
The experiments were conducted on two human breast cancer cell lines, namely,
the hormone-dependent breast cancer cell line, MCF-7 and the hormone-independent
breast cancer cell line, MDA-MB-231. These two cell lines are widely used in breast
cancer research and our lab has extensive experience in using these two cell lines to
measure steroid sulfatase activity.
MCF-7 cells are epithelial-like cells obtained from the pleural effusion of a 69-
year old Caucasian woman with metastatic breast adenocarcinoma. These cells grow as
monolayers and were described to be positive for cytoplasmic estrogen receptors (Soule
etal., 1973). Cells were obtained from American Type Culture Collection (ATCC,
Rockville, MD) and retain several characteristics of differentiated mammary epithelium
(ATCC, 2003). Tumor necrosis factor alpha inhibits growth of MCF-7 cells (Sugarman et
al., 1985). MCF-7 cells secrete insulin-like growth factor binding proteins (IGFBP) that
can be modulated by estrogens and antiestrogens (Pratt and Pollak, 1993).    
MDA-MB-231 cells were obtained from a 51-year old Caucasian female with
metastatic breast adenocarcinoma. They are epithelial-like cells and are estrogen receptor
negative (Cailleau et al., 1974). MDA-MB-231cells express high levels of transforming
growth factor alpha and epidermal growth factor receptor mRNAs (Bates et al., 1990).
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Test compounds
Several steroid hormones and agonists/antagonists, were tested for their effect on
steroid sulfatase activity, such as, estradiol, cortisol, estrone sulfate, EMATE and whole
growth media.
Assay design
Steroid sulfatase activity was determined by using conversion of [ 3H]E1S to [
3H]E1 and was slightly different as described by MacIndoe, 1988. The activity was
measured in estrogen-free media, after steroid hormone treatment.
Specific aim 1) (b) To determine the effect of various growth factors (prolactin,
oxytocin, IGF-1 and EGF) on steroid sulfatase activity in the hormone-independent breast
cancer cell line MDA-MB-231.
Model systems
The experiments were conducted on a human breast cancer cell line, MDA-MB-
231.
Test compounds
Oxytocin (0.2µM), prolactin (500 ng/ml), IGF-1 (2µg/ ml) and EGF (1µg/ml)
were tested (Braverman and Gurpide, 1986; Toniolo et al., 2000).
Assay design
Steroid sulfatase activity was determined by using conversion of [ 3H]E1S to [
3H]E1 (MacIndoe, 1988). The activity was measured in estrogen-free serum-free media,
after treatment with the various compounds.
15
Methods
Chemicals and Reagents
3H-estrone sulfate (ammonium salt, [6,7- 3H(N)]-; 49 Ci/mmol) and 3H-
dehydroepiandrosterone sulfate (sodium salt, [7- 3H]-; 16 Ci/mmol) were obtained from
DuPont/ New England Nuclear (Boston, MA). Radioinert steroids were obtained from
Sigma Chemical Co. (St. Louis, MO). Liquid scintillation cocktail was Ultima Gold
(Packard Instrument Co., Meriden, CT). EMATE was produced by the method of Purohit
et al. (1995). Toluene and Tris were acquired through Fisher Scientific (Pittsburgh, PA).
Trypsin-EDTA and Dulbecco’s Phosphate Buffered Saline (PBS) were purchased
through Sigma (St. Louis, MO).
Cell Culture and Media
MDA-MB-231 (hormone-independent) and MCF-7 (hormone-dependent) human
breast cancer cells were acquired from the American Type Culture Collection (Manassas,
VA). Cells were plated in 100 x 20 mm tissue culture dishes and medium was changed
every other day. Growth medium, which was used for routine cultures and cell growth
assays, was purchased from Sigma Chemical Co. (St. Louis, MO). Growth medium
consisted of RPMI-1640 (pH 6.9) supplemented with L-Glutamine (0.5mM), 25mM
HEPES (pH 7.5), 7.5% sodium bicarbonate (0.2% v/v), 5% fetal calf serum (FCS),
10mg/ml gentamicin (0.2% v/v) and antibiotic/antimycotic (10,000 units penicillin, 10
mg streptomycin and 25µg amphoterecin-B in one ml) (1% v/v). Cells were routinely
grown in 100mm tissue culture dishes in 10ml growth medium.
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Steryl Sulfatase Assay of Intact Cells after treatment with steroid hormones
MDA-MB-231 and MCF-7 cells in 100 x 20 mm tissue-culture dishes were
washed with 10 ml PBS for 1 min. After removing the PBS, 0.5 ml trypsin-EDTA was
added to the cells for 30 sec. The trypsin-EDTA was then removed and the dishes were
tapped in order to dislodge the cells. Cells were resuspended in 10 ml growth media.
Cells were counted using a hemocytometer. Five-hundred thousand cells were plated in
six-well plates and incubated overnight in whole growth media at 37° C. After the
incubation, the medium was removed and the cells were washed with PBS three times.
After that, the cells were incubated in 10µM or 1µM concentrations of cortisol, estradiol,
estrone sulfate or EMATE for 48 hours in estrogen-free medium. One molar stock
solution of these hormones was prepared in ethanol. These concentrations of steroid
hormones used were near physiological levels. One well per six-well plate containing
cells was left untreated. One well per six-well plate with no cells was used as a negative
control. After two days, the treatments were removed and the cells were washed three
times with PBS. The cells were then incubated with estrogen-free medium containing [
3H]E1S at 37° C for 18 h, after which 500µl medium from each well was pipetted into 13
x 100 mm borosilicate glass tubes in duplicate. Three milliliters of toluene were added to
each tube for extraction of unconjugated steroids. The mixture was vortexed for one min
and then centrifuged at 1000xg for five min at 4°C to separate the aqueous and organic
phases. One milliliter of the organic phase was removed from the tubes and placed into
scintillation vials in duplicate. Six milliliters of scintillation cocktail was added to each
vial. The radioactivity was counted using a Packard Tri-carb scintillation counter at 50%
efficiency for 3H. The conversion values obtained for all treatments were adjusted for
17
spontaneous product formation by substracting the value obtained for wells containing
medium but no cells. Product formation for samples containing test compounds was
compared to those of the control samples (no test compounds) and expressed as a
percentage of the control. Cells remaining after sulfatase assay were counted by MTT
assay.
Steroid sulfatase assay of MDA-MB-231 cells  after treatment with oxytocin,
prolactin, IGF-1 and EGF
 Five-hundred thousand cells were plated in six-well plates and incubated
overnight in whole growth media at 37° C. After the incubation, the medium was
removed and the cells were washed with PBS three times. After that, the cells were
incubated in the desired concentration of the respective treatments [0.2µM oxytocin,
(10mg stock); 500 ng/ml prolactin (50µg stock); 2µg/ ml IGF-1 (50µg) and 1µg/ml EGF
(0.2mg)] Sigma Chemical Co. (St. Louis, MO) for 48 hours in estrogen-free, serum-free
medium. One well per six-well plate containing cells was left untreated. One well per six-
well plate with no cells was used as a negative control. After two days, the treatments
were removed and the cells were washed three times with PBS. The cells were then
incubated with estrogen-free, serum-free medium containing [ 3H]E1S at 37° C.  After 18
h incubation, 500µl medium from each well was pipetted into 13 x 100 mm borosilicate
glass tubes in duplicate. Three milliliters of toluene was added to each tube for extraction
of unconjugated steroids. The mixture was vortexed for 1 min and then centrifuged at
1000xg for 5 min at 4°C to separate the aqueous and organic phases. One milliliter of the
organic phase was removed from the tubes and placed into scintillation vials in duplicate.
Six milliliters of scintillation cocktail was added to each vial. The radioactivity was
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counted using a Packard Tri-carb scintillation counter at 50% efficiency for 3H. The
conversion values obtained for all treatments were adjusted for spontaneous product
formation by substracting the value obtained for wells containing medium but no cells.
Product formation for samples containing test compounds was compared to those of the
control samples (no test compounds) and expressed as a percentage of the control. Cells
remaining after sulfatase assay were counted by MTT assay.
BCA Assay
The Pierce (Rockville, IL) BCA Protein Assay was used according to the
manufacturer’s instructions. A standard curve of bovine serum albumin was prepared
with water as the diluent. Duplicate concentrations (in µg/tube) were 200, 150, 125, 100,
75, 50, 30, 20, 10 and 5. A blank of only water was prepared. Membranes were prepared
as duplicates at differing amounts such that the volume of membrane and water equal 100
µl. Two milliliters of BCA working reagent was added to each tube, vortexed and
incubated in a 37°C waterbath for 30 min. Tubes were then allowed to be cooled to room
temperature and absorbances were read at 562 nm using a spectrophotometer. Standards
were plotted and the relationship between absorbance and concentration was determined
by linear regression. Unknown protein concentration was calculated from the regression
equation.
MTT Assay
Two hundred µl of MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide; Thiazolyl blue) solution (5 mg/ml in RPMI-1640) was added to each well of a
six-well plate containing cells (media removed) and incubated for three hours at 37°C.
At end of the incubation period, the converted dye was solubilized with one ml of acidic
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isopropanol. Aliquots of 100µl of the acidic isopropanol from a single well on the six-
well plate, were then transferred to each of eight consecutive wells on a 96-well
microtiter plate. Absorbance of converted dye was measured at a wavelength of 570 nm
with background subtraction at 690 nm. Absorbance of converted dye corresponded to
the number of cells. To generate standard curves, MDA-MB-231 and MCF-7 cells were
plated into six-well plates with each well containing a different number of cells obtained
by serial dilution. Cells were incubated in whole medium overnight prior to the MTT
assay to allow them to adhere to the plates. The relationship between cell number and
absorbances was determined by linear regression.
Statistical analysis
The various treatment groups were compared by one way analysis of variance
(ANOVA) with repeated measures. If a significant difference was found, then, Student-
Newman-Keuls test was used as a posteriori test. The statistical program used was Prism
(GraphPad Inc.).
20
Results
Effect on growth of the cells by the various compounds
One way analysis of variance showed that cells grown in steroid hormones at
1µM concentration had significant differences in cell number when assayed by MTT
(F=5.755, 4, 14 df, p<0.001). Cells grown in whole growth media were higher than
control cells (Student-Newman-Keuls test, p<0.05). One way analysis of variance also
showed significant differences in cell number in MDA-MB-231 cells treated with 10µM
concentration of steroid hormones (F=6.410, 4,19, df, p<0.001). Again, cells grown in
whole growth media showed higher cell number (Student-Newman-Keuls test, p<0.05).
One way analysis of variance on MCF-7 cells treated with 10µM steroid
hormones showed significant differences in cell number (F=3.769, 4,14, df, p<0.001).
Again, there was increase in cell number in MCF-7 cells treated with whole growth
medium (Student-Newman-Keuls test, p<0.05). One way analysis of variance (ANOVA)
did not reveal any significant differences in cell number in MDA-MB-231 cells treated
with growth factors (F= 0.4553, 4, 19 df, p<0.001).
As a result of these differences in cell number, data were normalized for cell
number prior to statistical analysis.
Steroid sulfatase assay of MDA-MB-231 cells after treatment with steroid hormones
MDA-MB-231 cells were treated with 1µM cortisol, estradiol, estrone sulfate or
EMATE. Steroid sulfatase activity was assayed by conversion of [ 3H]E1S to
unconjugated forms. The readings were expressed as percentage of control (Figure 2).
One way analysis of variance (ANOVA) showed significant differences among the
treatments (F= 11.26, 4,14 df, p<0.001). Cells treated with whole growth media showed a
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significant decrease in steroid sulfatase activity over control, cortisol, estradiol and
estrone sulfate (Student-Newman-Keuls test, p< 0.05).
MDA-MB-231 cells were treated with 10µM cortisol, estradiol or estrone sulfate.
Steroid sulfatase activity was assayed by conversion of [ 3H]E1S to unconjugated forms.
The readings were expressed as percentage of control (Figure 3). . One way analysis of
variance (ANOVA) indicated significant differences in steroid sulfatase activity among
groups (F= 8.638, 4,19 df, p<0.001). Cortisol showed a significant decrease in steroid
sulfatase activity over control but not over estradiol and estrone sulfate (Student-
Newman-Keuls test, p< 0.05). Cells grown in whole growth media also showed a
decrease in activity over control and all other treatment groups (Student-Newman-Keuls
test, p< 0.05).
Steroid sulfatase activity in MCF-7 cells treated with steroid hormones
MCF-7 cells were treated with 10µM concentration of cortisol, estradiol, estrone
sulfate or EMATE. Steroid sulfatase activity was assayed by conversion of [ 3H]E1S to
unconjugated forms. The readings were expressed as percentage of control (Figure 4).
One way analysis of variance (ANOVA) did not reveal any significant differences among
treatment groups (F= 1.897, 4, 14 df, p<0.001).
Steroid sulfatase activity in MDA-MB-231 cells treated with growth factors
MDA-MB-231 cells were treated with 0.2µM of oxytocin, 500 ng/ml of prolactin,
2µg/ml of IGF-1 or 1µg/ml of EGF for 48 hours. Steroid sulfatase activity was assayed
by conversion of [ 3H]E1S to unconjugated forms. The readings were expressed as
percentage of control (Figure 5).   One way analysis of variance (ANOVA) showed no
statistical differences among the treatment groups (F= 11.8, 4, 19 df, p<0.001).
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Figure 2: Steroid sulfatase activity in MDA-MB-231 cells after treatment with 1µM
cortisol, estradiol, estrone sulfate, EMATE or whole growth medium. MDA-MB-231
cells (0.5 million) were plated in six-well plates and incubated overnight in growth
medium. The growth medium was removed, cells were washed with PBS and incubated
for 48 hours in 1µM concentration of cortisol, estradiol, estrone sulfate and EMATE in
estrogen-free medium. Wells containing no cells were used as a blank and cells treated
with only estrogen-free medium were used as a control. Three wells were incubated in
whole growth medium. After 48 hours, the treatments were removed, cells were washed
with PBS and incubated in [ 3H]E1S for 18 hours. Steroid sulfatase activity was
determined and represented as percentage of control. Data are average of 3 experiments
with each experiment run in triplicate. Bars are +/- 1 standard error.
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Figure 3: Steroid sulfatase activity in MDA-MB-231 cells after treatment with 10µM
cortisol, estradiol, estrone sulfate or whole growth medium. MDA-MB-231 cells (0.5
million) were plated in six-well plates and incubated overnight in growth medium. The
growth medium was removed, cells were washed with PBS and incubated for 48 hours in
10 µM concentration of cortisol, estradiol and estrone sulfate in estrogen-free medium.
Wells containing no cells were used as a blank and cells treated with only estrogen-free
medium were used as a control. Three wells were incubated in whole growth medium.
After 48 hours, the treatments were removed, cells were washed with PBS and incubated
in [ 3H]E1S for 18 hours. Steroid sulfatase activity was determined and represented as
percentage of control. Data are average of 4 experiments with each experiment run in
triplicate. Bars are +/- 1 standard error.
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Figure 4: Steroid sulfatase activity in MCF-7 cells after treatment with 10µM cortisol,
estradiol, estrone sulfate, EMATE or whole growth medium. MCF-7 cells (0.5 million)
were plated in six-well plates and incubated overnight in growth medium. The growth
medium was removed, cells were washed with PBS and incubated for 48 hours in 10 µM
concentration of cortisol, estradiol, estrone sulfate and EMATE in estrogen-free medium.
Wells containing no cells were used as a blank and cells treated with only estrogen-free
medium were used as a control. Three wells were incubated in whole growth medium.
After 48 hours, the treatments were removed, cells were washed with PBS and incubated
in [ 3H]E1S for 18 hours. Steroid sulfatase activity was determined and represented as
percentage of control. Data are average of 3 experiments with each experiment run in
triplicate. Bars are +/- 1 standard error.
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Figure 5: Steroid sulfatase activity in MDA-MB-231 cells treated with 0.2µM of
oxytocin, 500 ng/ml of prolactin, 2 µg/ml of IGF-1 or 1µg/ml of EGF. MDA-MB-231
cells (0.5 million) were plated in six-well plates and incubated overnight in growth
medium. The growth medium was removed, cells were washed with PBS and incubated
for 48 hours in 0.2µM of oxytocin, 500 ng/ml of prolactin, 2µg/ml of IGF-1 or 1µg/ml of
EGF in estrogen-free, serum-free medium. Wells containing no cells were used as a blank
and cells treated with only estrogen-free, serum-free medium were used as a control.
After 48 hours, the treatments were removed, cells were washed with PBS and incubated
in [ 3H]E1S for 18 hours. Steroid sulfatase activity was determined and expressed as
percentage of control. Data are average of 4 experiments with each run in triplicate. Bars
are +/- 1 standard error.
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Discussion
The steroid sulfatase pathway is an important means of converting local inactive
estrogens to their active forms, thereby supporting tumor growth (Santner et al., 1986;
Reed and Purohit, 1997). A substantial amount of research has been performed in the
design of steroid sulfatase inhibitors, but the regulation of steroid sulfatase has been
largely overlooked. My research was to determine whether certain steroid hormones or
growth factors are involved in regulation of steroid sulfatase in human breast cancer cell
lines.
Two breast cancer cell lines were used for my study: the hormone-independent
MDA-MB-231 cells and the hormone-dependent MCF-7 cells. Both of these cell lines are
widely used in research of breast cancer and have been used in studies of steroid
sulfatase. MDA-MB-231 cells, used extensively by our laboratory, have more steroid
sulfatase activity than MCF-7 cells (Selcer et al., 1997). However, in the presence of
estrone sulfate as their only source of estrogenic steroid, the level of steroid sulfatase in
MCF-7 cells is sufficient enough to sustain their growth (Selcer et al., 1996).
The steroid sulfatase assay that I used has been previously shown to be an
effective method for determining steroid sulfatase activity in MCF-7 and MDA-MB-231
cells (Selcer et al., 2002; Kolli et al., 1999; Clemens et al., 2000). EMATE is an
extremely potent inhibitor of steroid sulfatase activity (Reed et al., 1995) and virtually
eliminates steroid sulfatase activity in breast cancer cell lines MDA-MB-231 and MCF-7
(Kolli et al., 1999). EMATE was added to the assay as a control. As expected, EMATE at
1µM concentration eliminated steroid sulfatase activity, indicating that the sulfatase assay
was working as expected.
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In the first set of experiments, steroid sulfatase activity was assayed after
treatment of MDA-MB-231 cells with 1µM cortisol, estradiol, estrone sulfate or
EMATE. Subsequently, 10µM cortisol, estradiol or estrone sulfate were used.
Cortisol decreased steroid sulfatase activity at 10µM concentration but not at
1µM concentration when compared with control and other treatment groups. Earlier work
in collaboration with J. Clemens showed that a potent synthetic glucocorticoid,
dexamethasone, decreased steroid sulfatase activity in rat granulosa cell line (POGRS-5)
(Clemens, J.W., unpublished data). Also, J. Clemens laboratory studied the steroid
sulfatase activity in an immortalized committed osteoprogenitor cell line OPC1. They
found approximately six-fold decrease in steroid sulfatase activity in OPC1 cells treated
with osteogenic supplement that contains dexamethasone (Clemens, J.W., Doctor, J.S.,
Olshansky, A., Sero, J., unpublished data). Thus, synthetic glucocorticoids seem to
decrease steroid sulfatase activity in a granulosa cell line and in OPC1 cells. My data also
supports that cortisol decreases the steroid sulfatase activity in human breast cancer cell
line, MDA-MB-231, at least at a 10µM concentration. This needs to be further evaluated
by determining the effect at different time intervals and using different concentrations of
steroid hormones.  Further studies can be carried out by doing protein analysis using
ELISA or Western blotting.  Also determining mRNA levels by RT-PCR can be done.
Estradiol and estrone sulfate did not change steroid sulfatase activity at 1µM or at
10µM concentrations in MDA-MB-231 cells. However, cells that were grown in whole
growth medium showed decrease in their steroid sulfatase activity. This growth media
contained fetal calf serum, which has a mixture of various different hormones. Hence,
one cannot pinpoint exactly which compounds are causing the decrease in the activity of
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steroid sulfatase. Possibly, there may be competitive inhibition due to the total amount of
sulfated steroids.
Hormone-dependent breast cancer MCF-7 cells were treated with 10µM cortisol,
estradiol or estrone sulfate, but no difference was observed among the treatment groups.
In the presence of estrone sulfate as their only source of estrogenic steroid, the level of
steroid sulfatase in MCF-7 cells is sufficient enough to sustain their growth, indicating a
possible role of steroid sulfatase in tumor growth (Selcer et al., 1996). The absence of any
effects might be because the cells have been grown in culture for many generations and
have lost their ability to respond to the treatment compounds. Alternatively, steroid
hormones may not regulate steroid sulfatase activity in this breast cancer cell line.
Hormone-independent human breast cancer cells MDA-MB-231 were treated
with various growth factors, including 0.2µM of oxytocin, 500 ng/ml of prolactin, 2µg/ml
of IGF-1 or 1µg/ml of EGF. These concentrations were based on previously published
research on these compounds (Braverman and Gurpide, 1986; Toniolo et al., 2000). My
results showed no significant difference among the treatment groups. Earlier report has
shown that there is increased conversion of estrone sulfate to estrone via steroid sulfatase
in vaginal deliveries than in cesarean deliveries and also that oxytocin inhibits this
activity once labor has started (Mitchell et al., 1984). Also, Braverman and Gurpide
(1986) showed that oxytocin and prolactin stimulate the activity of steroid sulfatase in the
placenta before the onset of labor and inhibit it after labor has started. These data suggest
a role of oxytocin and prolactin in the regulation of steroid sulfatase. However, my results
showed no effect in the hormone-independent MDA-MB-231 cells after treatment with
29
oxytocin and prolactin. Further studies could be carried using different concentrations of
these growth factors.
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CHAPTER 3
Experimental design
Specific aim 2) To screen various human tissues for steroid sulfatase status using
immunohistochemistry.
Model systems
The experiment was conducted on various human tissues, including placenta,
skin, skeletal muscle, liver, normal breast, breast carcinoma (ER+/PR+), breast
carcinoma (ER-/PR-), uterine carcinoma, adrenal gland, lung, brain, ovarian carcinoma
and prostate that were obtained from Spring Bioscience (Fremont, CA).
Antibody
Steroid sulfatase antibody was prepared by aligning cDNA sequences of human,
rat and mouse steroid sulfatases and selecting a conserved region. A peptide was
synthesized with this sequence and injected in rabbits as an antigen. The antisera that was
collected was used as primary antibody. This antisera has been shown by Western blot to
bind to steroid sulfatase in various tissues, including human placenta, human breast
cancer cells (MCF-7 and MDA-MB-231), rat liver, rat granulosa cells, porcine ovaries
and monkey ovaries (Selcer et al., 2001).
Assay design
Screening of various tissues for steroid sulfatase presence was carried out by
immunohistochemistry. Later, these tissues were scored for steroid sulfatase
immunoreactivity on a scale of 0 –3, with 0 representing no steroid sulfatase
immunoreactivity and 3 representing the highest immunoreactivity.
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Methods
Steroid sulfatase immunohistochemistry
Tissues were obtained from Spring Bioscience (Fremont, CA). Thirteen different
human tissues were screened for steroid sulfatase presence, including placenta, skin,
skeletal muscle, liver, normal breast, breast carcinoma (ER+/PR+), breast carcinoma
(ER-/PR-), uterus carcinoma, adrenal gland, lung, brain, ovarian carcinoma and prostate.
Tissues were deparaffinized in xylenes for five min, two times. This was followed by
incubating in dilutions of ethanol (100%, 95%, 70%, 50% and 30%) for two min. The
slides were then immersed in tap water for five min. Antigen retrieval was done by
immersing the slides in 10mM citrate buffer, pH 6.0, and followed by heating in a
microwave at high, medium and low power for five min each. The slides were then
allowed to cool to room temperature. This was followed by quenching of endogenous
peroxidase by incubating the slides in 3% hydrogen peroxide for six min. The slides were
then washed with PBS three times for five min followed by incubating in blocking
solution (Vectastain Elite ABC kit, Vector laboratories, CA) for 30 min. Slides were then
divided into two halves by tearing the tissue with a razor blade followed by using nail
polish so as to keep the treatments separate. One half was incubated with primary
antibody and the other with preimmune sera at room temperature for one hour or at 4°C
overnight. After that, slides were washed with PBS three times for five min each. Slides
were then incubated in secondary antibody (Vectastain biotinylated antirabbit IgG) for 30
min. This was followed by incubation in Vectastain Elite ABC Reagent for 30 min. After
that slides were washed in PBS three times, for five min each. Slides were then incubated
in DAB reagent for two min. The reaction was stopped by washing with tap water. Slides
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were then counterstained with Hematoxylin QS (Vector laboratories, CA) for 30 s and
washed with tap water to get rid of excess stain. Slides were later dehydrated in a 75%,
80%, 95% and 100% ethanol series for two min each. They were cleared by immersing in
xylenes twice for five min each.  Slides were mounted in Permount (Fisher Scientific,
NJ).
After immunohistochemistry, slides were scored for steroid sulfatase status. A
scale of 0 – 3 was used, with zero representing no steroid sulfatase immunoreactivity and
three representing the highest immunoreactivity. Three slides of each tissue was read by a
third party in a blind fashion. On a particular slide, four different regions were read and
scored from 0 – 3. Average of the readings were taken and a final steroid sulfatase score
was assigned to each tissue. Images of the tissues were also taken and permanently
stored.
Protein A chromatography
The steroid sulfatase antiserum was thawed and sodium azide was added to a final
concentration of 0.05%. The antiserum (2.5ml) was clarified by centrifugation at 15,000
x g for five min at 4° C. 500µl of this antiserum was saved. The remaining clarified
antiserum was passed through the column twice at the rate of two ml per min. The wash
was saved. The column was then washed with TBS (50mM Tris-HCl, pH 7.4; 150mM
NaCl; 0.05% sodium azide) with 10-fold of the volume (25 ml) of antiserum was loaded
onto the column. Centrifuge tubes (1.5ml) for collection of eluted sample were filled with
100µl of neutralization buffer (NB; 1M Tris-HCl, pH 8.0; 1.5M NaCl; 1mM EDTA;
0.5% sodium azide). The antibody was eluted (1 ml in each centrifuge tube) first using
15ml of elution buffer (50mM Glycine-HCl, pH 2.7) and later using 10ml of elution
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buffer (50mM glycine-HCl, pH 1.9) at room temperature. Coomassie Bradford protein
assay was carried out and the appropriate fractions were pooled. The purified antibody
was stored at 2 - 8° C. The same procedure was used to purify the preimmune sera.         
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Results
Immunohistochemical analysis was carried out on various human tissues. Tissues
were scored for steroid sulfatase immunoreactivity from 0 – 3, with zero being no steroid
sulfatase immunoreactivity and three being the highest steroid sulfatase immunoreactivity
detected. Tissues were then graded into three categories: high, moderate and low; where
high is having steroid sulfatase immunoreactivity greater than two, moderate is having
steroid sulfatase immunoreactivity between 1 –2 and low is having steroid sulfatase
immunoreactivity less than one. Slides of placenta, liver, normal breast, breast carcinoma
(ER+/ PR+) and skeletal muscle showed high immunoreactivity for steroid sulfatase.
Skin, lung, brain and uterine carcinoma showed moderate steroid sulfatase
immunoreactivity, whereas, adrenal gland, breast carcinoma (ER-/ PR-), ovarian
carcinoma and prostate had very low steroid sulfatase immunoreactivity.
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Figure 6: Immunohistochemical analysis for steroid sulfatase of various human tissues.
See methods for the procedure. Slides were scored for steroid sulfatase status. A scale of
0 – 3 was used, with zero representing no activity and three representing the highest
activity. Key to abbreviations: PCA – Placenta; SKN – Skin; LVR – Liver; LNG – Lung;
ADL – Adrenal; NBT – Normal breast; BC+ - Breast carcinoma (ER +/ PR+); BC- -
Breast carcinoma (ER -/ PR-); UTC – Uterus carcinoma; OVC – Ovarian carcinoma;
SKM – Skeletal muscle; BRN – Brain; PRT – Prostate.
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Placenta- steroid sulfatase antisera
Placenta- preimmune sera
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Liver- steroid sulfatase antisera
Liver- preimmune sera
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Skin- steroid sulfatase antisera
Skin- preimmune sera
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Breast carcinoma (ER/PR-+/+)- steroid sulfatase antisera
Breast carcinoma (ER/PR-+/+)- preimmune antisera
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Breast carcinoma (ER/PR -/-)- steroid sulfatase antisera
Breast carcinoma (ER/PR-/-)- preimmune sera
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Adrenal gland- steroid sulfatase antisera
Adrenal gland- preimmune sera
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Figure 7: Slides showing immunohistochemical analysis for steroid sulfatase of various
human tissues. See methods for the exact procedure. For each slide, one side was treated
with purified steroid sulfatase antiserum and the other side was treated with purified
preimmune serum. Slides were counterstained with hematoxylin
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Discussion
Steroid sulfatase has been suggested as a prognostic indicator for breast cancer
(Suzuki et al., 2003; Miyoshi et al., 2003), based mainly on studies of steroid sulfatase
mRNA. Immunohistochemistry may also be useful to determine if steroid sulfatase is
indeed of value as a marker. I sought to employ immunohistochemistry to screen various
human tissues for steroid sulfatase status. Tissues were obtained from Spring Bioscience
(Fremont, CA).
Not much information is available on the tissues that were obtained from Spring
Bioscience. They only mention the site from where the tissue was obtained and that it
was meant for immunohistochemical studies. Hence, more studies need to be carried out
in future with tissues that provide with more information about the source.
The steroid sulfatase antibody used by other laboratories was prepared by
purifying the steroid sulfatase protein to some extent and then injecting it in rabbit or
mouse to get the antibody (Miki et al., 2002). However, our steroid sulfatase antibody
was prepared by a different approach. Steroid sulfatase cDNA sequences of human, rat
and mouse were aligned and a conserved region was selected. A peptide was synthesized
using this sequence and injected in rabbits to get the antisera. By Western blotting of
microsomal preparations of placenta, MCF-7 and MDA-MB-231 cells, this antiserum
crossreacted with 66kDa protein that is the reported size of steroid sulfatase (Selcer et al.,
2001). This band was eliminated when the Western was carried out after the antiserum
was exposed to the peptide fragment used to generate the antiserum. The antisera have
also been shown by Western blotting to bind to microsomal preparations of rat liver, rat
granulosa cells, porcine ovaries and monkey ovaries. The preimmune and the immune
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sera were purified by protein A chromatography, checked by ELISA and used for
immunohistochemistry.
Miki et al., 2002, similarly screened various human adult and fetal tissues looking
for steroid sulfatase immunoreactivity and steroid sulfatase mRNA. This group found
steroid sulfatase immunoreactivity only in adult placenta, and mRNA expression was
undetectable or present in very low levels in most of the adult and fetal tissues screened.
My findings show high steroid sulfatase immunoreactivity in placenta, liver, normal
breast, breast carcinoma (ER+/ PR+) and skeletal muscle. Skin, lung, brain and uterine
carcinoma showed moderate steroid sulfatase immunoreactivity, whereas, adrenal gland,
breast carcinoma (ER-/ PR-), ovarian carcinoma and prostate had very low steroid
sulfatase immunoreactivity.
Placenta has high steroid sulfatase immunoreactivity and that was confirmed by
my findings (Shankaran et al., 1991). Defect in the enzyme steroid sulfatase causes X-
linked ichthyosis that affects males with generalized scaling of the skin (DiGiovanna and
Robinson-Bostom, 2003). This supports the finding of moderate immunoreactivity of
steroid sulfatase in the skin. Steroid sulfatase is present in liver and brain (Shankaran et
al., 1991). Moreover, steroid sulfatase levels have been found to increase in maternal
brain after delivery and during lactation (Mortaud et al., 1996). In vitro studies have also
shown that the steroid sulfatase pathway is active in producing free steroids in carcinoma
cells of vaginal, ovarian and endometrial uterine carcinomas (Milewich and Porter,
1987).
Miyoshi et al., 2003, showed that steroid sulfatase mRNA levels are elevated in
ER-positive breast cancer but not in ER-negative breast cancers (Miyoshi et al., 2003).
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My findings support that. I found that human breast carcinoma (ER+/ PR+) had high
steroid sulfatase immunoreactivity whereas human breast carcinoma (ER-/ PR-) had
minimal immunoreactivity for steroid sulfatase. Suzuki et al. (2003) studied the steroid
sulfatase immunoreactivity in human breast cancer and found that steroid sulfatase
expression was present only in carcinoma cells. They also found that steroid sulfatase
immunoreactivity was associated with increased recurrence and poor prognosis. These
data suggest that steroid sulfatase could be used as an independent prognostic marker for
breast cancer.
Here, I screened various different tissues for steroid sulfatase status and
established a protocol. I found a significant difference between estrogen-positive breast
cancer and estrogen-negative breast cancer. The next logical step would be to screen
breast cancer tissues for steroid sulfatase status and evaluate its role with other prognostic
markers like tumor size, lymph node involvement, distant metastasis and estrogen-
positivity. Additionally, one could examine the effect of Tamoxifen, a nonsteroidal
competitive inhibitor of estrogens, a drug used in treatment of estrogen-positive breast
cancer, on steroid sulfatase status (Dhingra, 2001). The eventual goal would be to
evaluate steroid sulfatase as a prognostic marker for relapse and to further refine the
diagnosis and treatment of breast cancer.
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